Acute Transient Aminotransferase Elevation is Common With Intrathecal Methotrexate, but Liver Injury is Infrequent
Liver International · 2025
DOI: 10.1111/liv.70022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, 2025. Verfasst von Harish Gopalakrishna und 4 weiteren Autor:innen. Beteiligte Einrichtung: Liver & Energy Metabolism Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of He…. Hauptthemen laut MEDLINE: Methotrexate, Chemical and Drug Induced Liver Injury, Alanine Transaminase, Aspartate Aminotransferases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, CCR NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Background and Aims Hepatotoxicity is a known risk of oral and intravenous methotrexate (MTX), but whether intrathecal (IT) administration causes hepatotoxicity remains unknown. We aimed to explore whether IT‐MTX causes acute hepatoxicity.
Methods
Retrospective single‐centre analysis of all patients treated with IT‐MTX from 2000 to 2020. We compared liver enzymes (LE) at baseline (within 7 days before IT‐MTX) to post‐MTX (within 7 days after IT‐MTX). LE elevation was defined as ≥ 50% increase in LE from baseline and greater than upper limit of normal. Drug‐induced liver injury (DILI) was defined based on established criteria.
Results
A total of 270 patients (184 adults and 86 paediatric) received IT‐MTX and had available LE data. Aminotransferase elevation was seen post‐MTX in 107 (40%) patients, of whom 96 (36%) had ALT and 68 (25%) had AST elevation. DILI occurred in 16 (6%) patients. Aminotransferases peaked a median of 4 (3–5) days post‐MTX, returning near baseline by day 7. Paediatric patients had higher incidence of aminotransferase elevations and DILI than adults (ALT 51% vs. 28%; AST 41% vs. 18%; DILI 11% vs. 3%; p < 0.01 for all). No significant predictors of LE elevation or DILI were identified, and no patient developed liver failure. The severity of ALT elevation after the first IT‐MTX dose did not predict severity of a subsequent dose.
Conclusion
Acute transient aminotransferase elevation is common after IT‐MTX, especially in paediatric patients. Only a fraction of patients developed DILI, which was self‐limited with no sensitisation or liver failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Liver & Energy Metabolism Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
- Liver Unit, Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada.
- Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
- Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
ORCID-Profile: Julian Hercun, Yaron Rotman
Förderung
- NIDDK NIH HHS
- CCR NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
- Center for Cancer Research
Zitieren
APA
Gopalakrishna, H., Hercun, J., Shah, N. N., Roschewski, M., & Rotman, Y. (2025). Acute Transient Aminotransferase Elevation is Common With Intrathecal Methotrexate, but Liver Injury is Infrequent. Liver International. https://doi.org/10.1111/liv.70022
Vancouver
Gopalakrishna H, Hercun J, Shah NN, Roschewski M, Rotman Y. Acute Transient Aminotransferase Elevation is Common With Intrathecal Methotrexate, but Liver Injury is Infrequent. Liver International. 2025. doi:10.1111/liv.70022
BibTeX
@article{Gopalakrishna2025,
author = {Gopalakrishna, Harish and Hercun, Julian and Shah, Nirali N and Roschewski, Mark and Rotman, Yaron},
title = {Acute Transient Aminotransferase Elevation is Common With Intrathecal Methotrexate, but Liver Injury is Infrequent},
journal = {Liver International},
year = {2025},
doi = {10.1111/liv.70022}
}
EUVIMED